Dicerna Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors
News Apr 18, 2014
Dicerna Pharmaceuticals, Inc. has announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma.
DCR-MYC, Dicerna's first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma.
"The MYC oncogene has been a therapeutic target of great interest for many years because of its expression in a variety of tumor types and the demonstration that increased MYC expression is related to the progression of these cancers," commented Anthony W. Tolcher, M.D., Director of Clinical Research at Southern Texas Accelerated Research Therapeutics, a principal investigator in the study. "The DsiRNA approach holds the possibility to overcome the challenges faced by previous drug development efforts to modulate this important target by directly interfering with the expression of MYC."
"In preclinical studies, DCR-MYC demonstrated impressive knockdown of the MYC oncogene," stated Pankaj Bhargava, M.D., Chief Medical Officer of Dicerna. "The Phase 1 trial of DCR-MYC now provides us the opportunity to test these promising data in clinical trials, furthering our efforts to realize the significant therapeutic potential of Dicer Substrate RNA interference."
"Genetic Jenga" Helps Understand How Our Genes Control Our CellsNews
To fully understand how our cells work, we can't focus on just one gene, but must instead look at combinations of genes. Researchers have published a study which knocked out multiple genes, like removing bricks from a Jenga tower, to better understand how they work together.READ MORE
Southeast Asian Nomads Have Evolved to Hunt Fish UnderwaterNews
The human spleen can release oxygenated blood cells to allow more time underwater without breathing. A new study has identified that the "Sea Nomad" Bajau people of Indonesia have evolved larger spleens that would allow them to remain underwater for longer.READ MORE
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018